DNMT3A、FLT3-ITD合并NPM1基因突变正常核型急
性髓系白血病患者的临床特征及预后分析
孙妍珺;徐杨;杨贞;田竑;田孝鹏;沈宏杰;仇惠英;陈苏宁;吴德沛
【期刊名称】《白血病·淋巴瘤》 【年(卷),期】2015(024)009
【摘要】Objective To analyze clinical characteristics of cytogenetically normal acute myeloid leukemia (CN-AML) patients with DNMT3A, FLT3-ITD and NPM1 mutations (DNMT3A/FLT3-ITD/NPM1+),and explore the prognosis of these patients.Methods The clinical characteristics and prognosis of 109 CN-AML patients in our center from Dec 2005 to Oct 2014 were retrospectively analyzed.Based on gene mutations, these patients were divided into 4 groups: DNMT3A/FLT3-ITD/NPM1+ AML patients (n =25), FLT3-ITD+ AML patients (n =32), NPM1+ AML patients (n =24), DNMT3A+ AML patients (n =28).Results The average age of 25 DNMT3A/FLT3-ITD/NPM1 + patients was 46 years old, including 9 males and 16 females.Higher white blood cells (81.7×l09/L) and bone marrow blasts (66.3 ％) were found in DNMT3A/ FLT3-ITD/NPM1+ group.The 3 years overall survival (3-OS) rate and 3 years disease free survival (3-DFS) rate in DNMT3A/FLT3-ITD/NPM1+ group were 17.65 ％ and 13.88 ％, respectively.In DNMT3A/FLT3-ITD/NPM1+ group, 17 patients received chemotherapy as consolidation therapy, and 8 patients received allogeneic hematopoietic stem cell transplantation
DNMT3A、FLT3-ITD合并NPM1基因突变正常核型急性髓系白血病患者的临床特
